Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer
Open Access
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 141, 111827
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapiesEuropean Journal of Cancer, 2014
- Monitoring Monoclonal Antibody Delivery in Oncology: The Example of BevacizumabPLOS ONE, 2013
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialThe Lancet Oncology, 2013
- Evidence for Therapeutic Drug Monitoring of Targeted Anticancer TherapiesJournal of Clinical Oncology, 2012
- A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancerCancer Chemotherapy and Pharmacology, 2011
- Population Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Therapeutic Monoclonal Antibody Concentration Monitoring: Free or Total?Bioanalysis, 2010
- Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical TrialsThe Journal of Clinical Pharmacology, 2009
- Clinical pharmacokinetics of bevacizumab in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2008
- Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteinsExpert Opinion on Biological Therapy, 2005